Monoclonal antibodies for broad-range treatment of neurodegenerative diseases

Written by Courtney Johnson

A research team led by Fernando Goni and Thomas Wisniewski at the Center for Cognitive Neurology at New York University Langone (NY, USA) have developed three types of IgM monoclonal antibodies (mAbs) that may offer promise for the treatment of a range of neurodegenerative diseases. The study, which sought to determine the binding specificity and capacity of the mAbs to target disease-causing toxic aggregates, was presented recently at the 2015 Alzheimer’s Association International Conference (Washington, DC, USA; 18–23 July 2015). It is well established that neurodegenerative diseases, such as Alzheimer’s, Parkinson’s and GSS (human prionosis) have a similar pathogenesis involving...

To view the full article, please register now for access

It's completely free